Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Cullinan Therapeutics (CGEM) Operating Income (2020 - 2023)

Cullinan Therapeutics (CGEM) has 4 years of Operating Income data on record, last reported at -$45.5 million in Q4 2023.

  • For Q4 2023, Operating Income changed N/A year-over-year to -$45.5 million; the TTM value through Dec 2023 reached -$191.1 million, changed N/A, while the annual FY2024 figure was -$196.9 million, 3.05% down from the prior year.
  • Operating Income reached -$45.5 million in Q4 2023 per CGEM's latest filing, down from -$45.2 million in the prior quarter.
  • Across five years, Operating Income topped out at $239.7 million in Q2 2022 and bottomed at -$62.8 million in Q1 2023.
  • Average Operating Income over 4 years is -$8.0 million, with a median of -$23.8 million recorded in 2020.
  • The widest YoY moves for Operating Income: up 1543.5% in 2022, down 2480.25% in 2022.
  • A 4-year view of Operating Income shows it stood at -$29.2 million in 2020, then decreased by 17.74% to -$34.3 million in 2021, then surged by 797.82% to $239.7 million in 2022, then tumbled by 118.98% to -$45.5 million in 2023.
  • Per Business Quant database, its latest 3 readings for Operating Income were -$45.5 million in Q4 2023, -$45.2 million in Q3 2023, and -$37.6 million in Q2 2023.